home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
DP Tool Club 17
/
CD_ASCQ_17_101194.iso
/
vrac
/
med9408d.zip
/
M9480804.TXT
< prev
next >
Wrap
Text File
|
1994-08-27
|
3KB
|
41 lines
Document 0804
DOCN M9480804
TI Combination therapy for infection due to human immunodeficiency virus
type 1.
DT 9410
AU Caliendo AM; Hirsch MS; Infectious Disease Unit, Massachusetts General
Hospital, Boston; 02114.
SO Clin Infect Dis. 1994 Apr;18(4):516-24. Unique Identifier : AIDSLINE
MED/94312547
AB The preliminary results of the Concorde trial demonstrated the transient
clinical benefit of monotherapy with zidovudine (AZT) in asymptomatic
persons infected with human immunodeficiency virus type 1 (HIV-1). This
result, which has been widely disseminated and discussed, was
predictable given the previous demonstration of the development of
resistance to AZT in isolates from individuals receiving prolonged
treatment with the drug and given the finding that didanosine (ddI) is
more efficacious than continued therapy with AZT in individuals who have
received > or = 6 months of AZT monotherapy. On the basis of these
findings, interest in combinations of antiretroviral agents has
continued to grow. Many in vitro studies of nucleoside and nonnucleoside
inhibitors of reverse transcriptase combined with interferon-alpha or
inhibitors of protease have been published. In addition, numerous
clinical trials of various combinations have been completed or are under
way. Dr. Martin Hirsch and his colleagues at the Massachusetts General
Hospital have been among the leaders of this effort. He and Dr. Angela
Caliendo review, in this AIDS Commentary, the current state of our
knowledge regarding the potential utility of combination therapy for
infection with HIV-1.
DE Acyclovir/ADMINISTRATION & DOSAGE Antigens, CD4/ADMINISTRATION & DOSAGE
Antiviral Agents/*ADMINISTRATION & DOSAGE Clinical Trials Combined
Modality Therapy Didanosine/ADMINISTRATION & DOSAGE Drug Therapy,
Combination Foscarnet/ADMINISTRATION & DOSAGE Human HIV
Infections/*DRUG THERAPY/THERAPY *HIV-1 In Vitro Interferon
Alfa-2a/ADMINISTRATION & DOSAGE Reverse Transcriptase/ANTAGONISTS &
INHIB Zalcitabine/ADMINISTRATION & DOSAGE Zidovudine/ADMINISTRATION &
DOSAGE JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).